The clinical study NEUROSIS is an international multicentre clinical study which assessed the impact of inhaled budesonide on bronchopulmonary dysplasia (BPD), a frequent cause of morbidity and mortality in preterm infants.
Positive results of the clinical study NEUROSIS
The clinical study NEUROSIS is an international multicentre clinical study which assessed the impact of inhaled budesonide on bronchopulmonary dysplasia (BPD), a frequent cause of morbidity and mortality in preterm infants. It was conducted with the support and cooperation of Chiesi by a European consortium of experienced neonatologists, funded by the European Union, according to its 7th Framework program.
For the first time an inhaled corticosteroid was tested on a population of 850 preterm infants at risk for bronchopulmonary dysplasia.
The treatment with budesonide significantly reduced the frequency of appearance of BDP, with a good safety profile for the infants.
Infants are monitored until the age of 22 months, to assess the long term consequences of budesonide treatment.
